MicahRFisherMD

Pulmonology • Atlanta, GA

Critical Care Medicine, Pleural Disease, Pulmonary Vascular Medicine

Associate Professor, Medicine, Emory University School of Medicine

Join to view full profile

Dr. Fisher is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fisher's full profile

Already have an account?

Office
1365 Clifton Rd, Building A
Suite A3229
Atlanta, GA 30322
Phone+1 404-778-3261

Fax+1 404-778-4431

Education & Training

Johns Hopkins UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2005
University of Pennsylvania Health SystemResidency, Internal Medicine, 1999 - 2002
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 1999

Certifications & Licensure

GA State Medical License 2005 - 2025
MD State Medical License 2003 - 2006
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Clinical Trials

Comparative Evaluation of Albumin and Starch Effects in Acute Lung Injury (ALI) Start of enrollment: 2009 Jan 01
Terminated
Phase 3
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy Start of enrollment: 2012 Jun 26
Completed
Phase 3
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension Start of enrollment: 2013 Sep 11
Completed
Phase 3
Beraprost-314d Added-on to Tyvaso® (BEAT) Start of enrollment: 2013 May 31
Completed
Phase 3
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis Start of enrollment: 2016 Feb 01
Withdrawn
Phase 2
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH Start of enrollment: 2018 Jul 15
Terminated
Phase 2
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 Start of enrollment: 2019 Apr 10
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Evaluation of right ventricular strain in two separate cohorts with precapillary pulmonary hypertension.
Lauren M Crossman, Priyanka Rajaram, Charles Michael Hart, Maria A Pernetz, Anurag Sahu
Pulmonary Circulation. 2023-01-01
15 citations
BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hyperten...
Leslie A Spikes, Abubakr A Bajwa, Charles D Burger, Sapna V Desai, Michael S Eggert
Pulmonary Circulation. 2022-04-01
6 citations
Effect of pulmonary hypertension on 5-year outcome of kidney transplantation.
Fadi Rabih, Rhiannon L Holden, Payaswini Vasanth, Stephen O Pastan, Micah R Fisher
Pulmonary Circulation. 2022-01-01